gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
The vaccine primes neoantigen-specific T cells. CD8+ CTLs kill tumor cells presenting the neoantigen via MHC I (perforin/granzyme, Fas–FasL), and CD4+ T cells recognizing the MHC II epitope provide help and can directly lyse MHC II–positive tumor cells.
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
Personalized somatic mutation–derived CD4+ T-cell target; presented on HLA class II
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06631079
disease_id_num_tar_ref
3723
drug_id_num_tar_ref
10063